Lenfant T, Jin Y, Kirchner E, et al. - Whether Recombinant Zoster Vaccine (RZV) is safe for patients suffering from Immune-Mediated Inflammatory Diseases (IMID) was explored herein. Participants were retrospectively included and involved patients who were administered RZV in a single center Rheumatology Department. Overall, 622 patients were analyzed (67% women, median age 67 years), of those, 8.5% had AEs and HZ incidence was estimated to be 0.6% following median observation of 36 weeks. Among 359 IMID cases, 88 had RA (25%), 50 vasculitis (14%), 29 PMR (8%). Findings revealed a general good tolerability of RZV administration in patients with IMIDs, however, it was not uncommon to experience mild flares in the first 12 weeks post-vaccination. These findings may afford beneficial data for patient education when considering RZV use.